Key facts
- Caidya’s last known valuation is $1.0B (Jul 2021).
- It has raised $375.1M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($100.0M) in Dec 2020.
- Notable investors include Sequoia Capital, Hongshan Capital Group, Fidelity Management & Research Company, Qiming Venture Partners, Legend Star — 22 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Caidya
Funding rounds
1 roundsAbout Caidya
Operator of a bio-pharmaceutical-based contract research organization (CRO) designed to facilitate the globalization of drugs. The company's research organization provides advisory services based on clinical development plans, regulatory strategies, approval processes, and clinical trial support, enabling medical companies to improve clinical trial efficiency and thereby increase the probability of their product's success.
- Industry
- Other Healthcare Services
- Sector
- Healthcare
- HQ
- Raleigh, NC, United States
- Founded
- 2004
- Employees
- 1,800
- Website
- caidya.com/
- Ownership
- Privately Held (backing)
Caidya doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Caidya shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Caidya in its N-PORT filings yet. We sweep new filings monthly.